Methodology: each issue's direction is a live signal — long/short opens or holds a position, neutral means flat, and every direction change opens, flips, or closes it. Returns are direction-aware (a short gains when the price falls) and compound across positions from first observation to the latest issue. "Price move" is the stock's own raw change, shown separately. Neither represents actual portfolio performance.
Brief History (13 issues)
Down 0.89% with a neutral RSI of 53.3, holding ~8% above the 50-day. Out-licensing of innovative drugs is the core thesis; 29 analysts target HK$118.02 for 32.5% upside — continue holding
Position: -1.3% on light volume — the innovative-drug globalization story runs on; healthy digestion after a +22% month, hold
Consolidating quietly after a +24.5% month as the biotech-globalization story runs; 31 analysts see +28% — hold
Down 5.57% Friday to HK$88.95 in the biotech-wide beatdown, just 1.1% above the HK$88 stop — a close through the line means out, no waiting for a second red candle. Long above it.
Down 3.0% this morning at HK$91.35 as innovative drugs caught the CXO panic, 3.7% above the HK$88 stop — inside the discipline line, holding
Flat this morning at HK$97.00, one step from the round number — RSI 72 runs hot but the innovative-drug theme is +24.4% on the month; stop raised to HK$88, holding
Up 1.1% this morning at HK$90.05, extending the swing high — the innovative-drug theme is +22.5% on the month; holding
Up 3.9% as biotech absorbed the money fleeing chips; gains widening, the 20-day (HK$80.40) far below — holding
Up 4.8%, attacking in resonance with the CXO and biotech complex, +25.7% on the month; gains widening, holding
Up 1.8% with bids intact after a 20% month for the pharma innovator; the 20-day (HK$80) sits well below, holding
Flat, long +0.1%; innovative pharma consolidating at highs above the 20-day, hold
Innovative-pharma -3.4%, long -0.5%; revenue +38.6%, holds the 20-day, hold
Innovative-pharma leader up 15.3% on the week, revenue +38.6%, with 30 analysts nearly unanimous bulls